Pee Safe Secures $32 Million for Major Expansion Push
Personal hygiene brand Pee Safe has announced a significant funding round. The company raised $32 million, which is approximately ₹290 crore, from global healthcare-focused private equity firm OrbiMed Asia Partners and its existing investors. This Series C funding includes both primary and secondary shares, as confirmed in a company statement released on Wednesday.
Expansion Plans Across Retail and Digital Channels
The fresh capital will fuel an aggressive expansion strategy. Pee Safe intends to increase its offline retail footprint significantly. The brand also plans to strengthen its marketing efforts and expand its presence across quick commerce platforms and online marketplaces. The company did not disclose the exact amount of fresh capital raised in this round.
Pee Safe's product portfolio covers several categories. These include toilet hygiene, feminine and intimate hygiene, personal care, grooming, and wellness. Currently, the brand is available in 50,000 retail outlets spread across 100 cities. It also sells through leading e-commerce and quick commerce platforms.
Founder's Vision and Business Performance
Founder Vikas Bagaria explained the company's mission. "Pee Safe was founded to address a deeply underserved women's health category and challenge long-standing taboos," he said. "That focus has translated into a business built on strong fundamentals. Our ability to scale profitably reflects a disciplined, long-term approach. Partnering with OrbiMed, who share our conviction in the consumer healthcare opportunity, marks an important step in Pee Safe's next phase."
The company has achieved impressive financial growth. Pee Safe reported it has scaled to over ₹150 crore in annualised net revenue. For the fiscal year 2025, the company posted revenue from operations of ₹82 crore. This represents a 46% increase from ₹56 crore in the previous year. Its losses also narrowed significantly, dropping to ₹4 crore.
Previous Funding Rounds and New Board Members
This latest funding round follows previous investments. According to Traxcn, the company had raised a total of $16.5 million prior to this round, with Alkemi Growth Capital as the lead investor. In 2023, Pee Safe secured $3 million from investors led by Natco Pharma and Rainmatter Health.
OrbiMed's involvement brings new leadership to the company's board. Senior managing director Sunny Sharma and executive director Sumona Chakraborty will join Pee Safe's board as part of the investment.
About OrbiMed Asia Partners
OrbiMed is a major global healthcare investment firm. It manages approximately $20 billion across public and private company investments worldwide. The firm operates through offices in key healthcare hubs around the globe.
OrbiMed has been active in the Indian healthcare and wellness space. In 2024, it invested in ayurvedic wellness brand Kapiva. The firm also backed medtech company Innvolution Healthcare and generic drugmaker Marksans Pharma in 2023, among other investments.
This funding round positions Pee Safe for substantial growth in both physical retail and digital commerce channels across India.
